CSL Limited (CSLLY) est une société cotée en bourse dans le Santé secteur, opérant dans le Biotechnologie secteur d'activité. Le siège social de l'entreprise est situé à Melbourne, VIC, Australia. Le PDG actuel est Gordon Naylor DipCompSc.
CSLLY a date d'introduction en bourse 2009-12-29, 32,698 employés à temps plein, cotée sur le Other OTC, une capitalisation boursière de $95.92B.
CSL Limited is a global biopharmaceutical company headquartered in Parkville, Australia, with operations across the United States, Europe, China, and other international markets. The company operates through two primary divisions: CSL Behring, which specializes in plasma-derived and recombinant therapies for immunodeficiency, bleeding disorders, hereditary angioedema, and neurological conditions, and Seqirus, which focuses on non-plasma biotherapeutics and influenza-related products. CSL Limited researches, develops, manufactures, and distributes a comprehensive portfolio of biopharmaceutical products while also generating revenue through licensing and royalty agreements. Founded in 1916, the company has established itself as a leader in the biopharmaceutical industry through its innovative therapeutic solutions and global market presence.
